Phaseline

Companies › Janux Therapeutics

Janux Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JANX007
PSMA-targeting bispecific antibody
–Phase 1Prostate CancerJul 2027
JANX014
Bispecific antibody targeting PSMA and 4-1BB
–Phase 1Prostate CancerMay 2028
JANX013–Phase 1Prostate CancerJul 2029
JANX008
EGFR-targeting therapy
EGFRPhase 1Non-Small Cell Lung Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05783622JANX008Phase 1Non-Small Cell Lung CancerOncologyJul 2026
NCT05519449JANX007Phase 1Prostate CancerOncologyJul 2027
NCT07545811JANX014Phase 1Prostate CancerOncologyMay 2028
NCT07813637JANX013Phase 1Prostate CancerOncologyJul 2029
NCT07813637JANX007Phase 1Prostate CancerOncologyJul 2029

From the company's SEC filings

Cash and short-term investments of $946m on 2026-09-30; operating cash outflow about $34m a year; runway about 338 months at that burn, to Nov 2054

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.